Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG-PAM
- Development stage
- Preclinical
- Lead developer
- PAM THERAGNOSTICS
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
PEG-PAM is a PEGylated recombinant form of the peptidylglycine alpha-amidating monooxygenase (PAM) enzyme, currently in preclinical development by PAM Theragnostics. The drug is designed as an enzyme replacement therapy to address neurovascular dysfunction and blood-brain barrier (BBB) deterioration associated with Alzheimer's disease and other forms of cognitive decline. PAM is the sole enzyme responsible for the C-terminal amidation of many signaling peptides, a modification essential for their biological activity. By restoring PAM activity, PEG-PAM aims to activate protective vascular peptide hormones, such as adrenomedullin, which help maintain vascular integrity and counteract BBB damage. It is intended for weekly subcutaneous self-administration.
- Other names
- PAM Therapy
02
Targets
PAM (Peptidylglycine alpha-amidating monooxygenase)
Beyond the preview
Go deeper on PEG-PAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEG-PAM.